Conventional contrast-enhanced MR imaging is the current standard technique for the diagnosis and treatment evaluation of gliomas and other brain neoplasms. However, this method is quite limited in its ability to characterize the complex biology of gliomas and so there is a need to develop more quantitative imaging methods. Perfusion and permeability MR imaging are two such techniques that have shown promise in this regard. This review will highlight the underlying principles, applications, and pitfalls of these evolving advanced MRI methods.
Introduction
The current standard imaging technique to evaluate gliomas is contrastenhanced MR. However, this technique is not able to fully evaluate the complex underlying tumor biology of these neoplasms. Because conventional contrast-enhanced MR imaging is limited in its ability to differentiate between neoplastic and non-neoplastic disease, identify glioma grade, and detect the presence of residual or recurrent tumor versus treatment related effects (1, 2), advanced MR techniques such as perfusion and permeability MR imaging have generated recent attention.
Currently, the major MR perfusion techniques utilizing exogenous extracellular contrast for glioma imaging are dynamic susceptibility contrast (DSC) imaging and dynamic contrast-enhanced (DCE) imaging. DSC imaging has concerned itself mainly with tumor angiogenesis, while DCE imaging has been predominantly focused on evaluation of vascular permeability.
MR Perfusion Imaging Techniques

First-Pass (FP) Dynamic Susceptibility Contrast T2* Perfusion MRI (DSC MRI)
T2*-weighted DSC perfusion MR is the most commonly used technique for brain tumor perfusion. The most utilized and robust perfusion metric obtained by DSC imaging is relative cerebral blood volume (rCBV), typically expressed relative to normal appearing contralateral white matter (1, 3) . If the tumor appears to be within the cortex or deep gray nuclei, then rCBV measurements should be made relative to the contralateral normal appearing gray matter structure.
An in depth review of the principles underlying DSC perfusion is beyond the scope of this article, but a few basic concepts will be discussed. According to the indicator dilution theory, cerebral blood volume (CBV) is proportional to Technology in Cancer Research & Treatment, Volume 10, Number 1, February 2011 the area under the contrast agent concentration-time curve, assuming there is no contrast agent leakage and no recirculation. Based on the susceptibility signal intensity-time curve, the gadolinium contrast agent concentration, which is proportional to the change in relaxation rate ∆R2* [change in reciprocal of T2*] (or ∆R2 if spin-echo sequence is used) can be calculated from the signal intensity via the equation: ∆R2* = [-ln(S(t)/So]/TE where S(t) is the pixel signal intensity at time t, So is the pre-contrast signal intensity, and TE is the echo time (4). The equation is assumed to be valid if the T1 enhancement associated with a disrupted blood-brain barrier has a negligible effect on signal intensity -a situation uncommonly encountered in brain tumors. This will be further addressed below.
Most centers utilize a gradient echo-echo planar (GRE-EPI) technique using a standard dose of gadolinium contrast agent (0.1 mmol/kg, usually about 20 mL total) (5). Spin-echo (SE) sequences have been used and are mainly sensitive to smaller vessels under 20 μm, i.e. capillaries. GRE acquisitions are sensitive to vessels of all sizes, and therefore it is important to exclude macrovessels from regions of interest. The signal change measured with GRE is greater than that of SE, allowing the use of shorter TE's and lower contrast agent dose , 0.1 mmol/kg for GRE vs 0.2 mmol/kg for SE. rCBV acquired with GRE-EPI technique appears to better correlate with tumor grade compared with SE, likely due to the fact that high-grade tumors possess disorganized, largescale microvessels without the typical features of capillaries (6). To determine vascular diameter or size in patients undering going anti-angiogenic therapy, combined SE and GRE techniques can be performed (7, 8) .
Because it is less sensitive to susceptibility artifact, SE sequences can be advantageous at the skull base or at bonebrain-air interfaces (9, 10).
In general, the DSC imaging sequence duration is about a minute or so. The sampling rate (TR) should be below 2 seconds. The gadolinium contrast agent is injected typically through an 18 gauge catheter in a peripheral vein (0.1 mmol/ kg for GRE and 0.2 mmol/kg for SE). Injection rates range from 5 to 10 ml/sec followed by 20-30 ml of saline flush.
With echo-planar imaging and new parallel imaging techniques, whole brain coverage at one-second intervals can be achieved using both rapid gradient echo and spin echo techniques.
T1 Dynamic Contrast Enhanced (DCE) Imaging
A detailed description of the biophysical concepts of permeability imaging is beyond the scope of this paper. Those interested are referred to several excellent reviews on this topic (11, 12) . However, some basic principles will be discussed. In DCE imaging, a time-series of T1-weighted images are acquired following injection of gadolinium contrast agent to examine the vascular permeability of the brain. Vascular permeability of the brain is dependent on the cerebrovascular endothelium, also known as the blood-brain barrier [BBB]), which separates the intravascular and extracellular-extravascular space (EES). The BBB is disrupted in many brain tumors as well as many other pathologic processes, resulting in T1 contrast enhancement. Conventional post-contrast T1 weighted images offer a glimpse of enhancement at one time point (11).
The most commonly used and accepted MR permeability technique is a steady-state T1 weighted DCE method based on the pharmacokinetic model of Tofts and Kermode (13) . This allows calculation of concentration of gadolinium contrast agent in tissue to be calculated as a function of time after bolus injection of gadolinium contrast agent. Parameters such as permeability surface area of the endothelium (PS) and fractional size of the extravascular-extracellular space (v e ) as well as simpler metrics as initial slope, time to peak, and initial area under the contrast agent concentration-time curve are derived (1). K trans , the volume transfer constant describing the rate of flux of contrast agent into the extravascular-extracellular space, is the most frequently used metric in DCE MR imaging (14). K trans can have different interpretations depending on blood flow and permeability. In situations where there is very high permeability, flux of contrast agent is limited only by flow and so K trans mainly reflects blood flow. In situations where there is very low permeability, contrast agent cannot leak easily into the extravascular-extracellular space, and so K trans mainly reflects PS (15). Despite this complexity, K trans appears to reproducibly measure permeability in glioma patients (16) .
At our institution, we utilize an approach that combines T1 DCE and FP T2* DSC MRI (Figure 1) . A 3 to 4 minute long T1 DCE portion is run first, during which an injection of 0.05 mmol/kg (10 cc's) of gadolinium contrast agent is injected. This also serves as a preload contrast dose (discussed below) to help correct for leakage effects. Several types of fast gradient-echo sequences such as a 3D SPGR, MPRAGE, or VIBE sequence can be utilized. The temporal resolution is a scan every 5 seconds and the volume of brain coverage is dependent on the sequence, parameters and the use of parallel imaging schemes. Then an axial T2 scan can be performed. Subsequent to that, a 1 to 1.5 minute long FP T2* DSC sequence is performed. It is during this time that a second injection of 0.05 mmol/kg (10 cc's) of gadolinium contrast agent is injected. Post-processing can then be performed on a variety of available software packages.
Technical Pitfalls
Lack of Standardization
Currently there is no standardized method by which to acquire, post-process, and interpret perfusion data across institutions. This has obvious implications with regard to interpreting the usefulness and generalizability of perfusion values quoted in the literature.
Of particular interest is the manner by which region of interest (ROI) placement is performed when measuring rCBV using the commonly employed "hot-spot" method. In this technique, ROIs are placed within the tumor and corresponding normal appearing white (or gray) matter. This method is widely utilized, however, it is thought to have several key limitations including being highly operator dependent, sensitive to noise and other artifacts, and the fact that oligodendrogliomas tend to demonstrate elevated rCBVs regardless of grade (17, 18) . Recently Emblem et al. demonstrated the utility of histogram analysis as an alternative to the "hotspot" method with improved diagnostic accuracy and interobserver agreement (18).
Leakage Effects
Contrast agent leakage into the extravascular-extracellular space results in complex simultaneous changes in T1, T2 and T2* which can confound rCBV values (19). There have been many different ways in which authors have dealt with the troubling issue of leakage effects including dual echo T2* acquisitions, low flip angle GRE, preload dosing, mathematical correction and baseline subtraction techniques (6, 19, 20) .
Because of its relatively larger molecular size compared to gadolinium, another potential solution to the leakage issue may lie in the use of the non-gadolinium contrast agent ferumoxytol, an iron oxide nanoparticle, which appears to act as a blood-pool agent and not suffer from the leakage effects of gadolinium contrast agents (21). Preliminary work appears to demonstrate its utility in perfusion imaging of gliomas (22).
Susceptibility
DSC MRI is extremely sensitive to susceptibility effects resulting from blood products, calcium, bone, melanin, metals, or lesions near the brain-bone-air interface, particularly at the skull base.
Decreasing slice thickness can decrease susceptibility artifacts, at a cost of reducing the signal to noise ratio (SNR) and slice coverage. Another possible solution is to incorporate parallel imaging methods that can reduce both susceptibility and the scan time to allow for more brain coverage and SNR. The use of T1-weighted DCE could offer glioma, which is typically heterogeneous, as well as the surrounding brain parenchyma which is typically not resected nor biopsied.
Prior studies have demonstrated that rCBV values correlate well with glioma biology. Low-grade gliomas appear to have maximal rCBV values of between 1.11 to 2.14 and high-grade gliomas to have maximal rCBV values of between 3.54-7.32 (10, 28-30) (Figures 2 and 3) .
Compared with conventional contrast-enhanced MRI, perfusion MR appears to increase the sensitivity and predictive value in predicting glioma grade (31). Sensitivity of 95% to 100 % has been reported for differentiating high-grade from low-grade gliomas using thresholds of 1.75 and 1.5 for rCBV respectively (17, 28) with specificities of 57.5% to 69% using the same threshold values. The relatively lower specificity is due in part to a high number of false positiveswhere lowgrade gliomas with elevated rCBV can be misclassified as high-grade gliomas.
While most studies have used histopathological specimens as the gold standard, Law et al. (32) recently examined the value of rCBV measurements to predict glioma biology (Figure 4 ), using patient outcome, rather than histopathology, as the gold standard. In this study, there was a significant difference in time to progression in low-grade gliomas with baseline rCBV < 1.75 versus those with rCBV > 1.75. For high-grade gliomas, there was a significant difference in progression in those with rCBV > 1.75 compared with those < 1.75. Among subjects with low rCBV (rCBV < 1.75) there was a significant difference between highand low-grade tumors with respect to progression-free survival. However, among subjects with high rCBV (rCBV > 1.75), time to progression was not significantly different for low-and high-grade tumors. These results suggest that a glioma initially thought to be low-grade should be treated more aggressively if its baseline rCBV is high and that histology may underestimate glioma biology. Perhaps rCBV measurements from DSC MRI may overcome some of the limitations of the current histologic methods to predict tumor biology.
Other studies have derived higher rCBV values (2.91) to distinguish low-from high-grade gliomas (33). Emblem et al. obtained optimal normalized CBV threshold values of 3.75 to 5.58. The range of rCBVs quoted in the literature likely reflects differences attributable to technical considerations such as choice of sequence design and image acquisition, post-processing and interpretation methods, among others, and that perhaps, until a single standardized method becomes universal, rCBV thresholds to differentiate low-from high-grade gliomas should be based on each institutions' experience (18).
an alternative means of imaging as it is relatively resistant to susceptibility effects.
Perfusion and Permeability MR Imaging of High-Grade Gliomas
Glioma Grading Perfusion and Permeability MR Guidance of Brain Biopsy Despite numerous shortcomings such as reproducibility and sampling error, the WHO classification scheme remains the gold standard to grade brain tumors. While it may be currently true that most brain tumors will undergo biopsy and that, practically speaking, imaging-based prediction of glioma grade will not likely have a tremendous clinical impact, validation of non-invasive means of glioma grading is of critical importance as histopathologic undergrading of gliomas is common.
Brain biopsies have been traditionally guided with contrast-enhanced T1-weighted MR or CT images (23, 24). Contrast enhancement in these studies is a reflection of breakdown of the BBB and may not necessarily indicate the most malignant portion of the tumor. The most malignant portion of the tumor can often be found within the surrounding T2 signal abnormality and not necessarily where enhancement is present. In fact, it has been shown that 38% of anaplastic astrocyotomas do not display contrast enhancement and that up to 25% of brain tumors are under-graded at stereotactic biopsy (17, 25) . Perfusion and permeability MR may be useful to guide the surgeon toward the most vascular and malignant portion of the mass (5, 14, 26) .
Therapy for low-and high-grade gliomas is very different. High grade (WHO grade III and IV) gliomas are typically treated with surgery, either subtotal or gross total resection, and adjuvant chemoradiation. However, treatment for low-grade gliomas (WHO grade I and II) may vary from conservative to surgical resection. Because of the inherent risk and limitations of brain biopsy and the critical importance of accurate grading on management, there is a real need for a classification scheme that may serve as an adjunct, or potentially replace, histopathological grading (27).
Perfusion and Permeability MR in Predicting Glioma Biology
Unlike invasive brain biopsy, perfusion and permeability MR has the advantage of being non-invasive (except for contrast administration), a fact that would easily allow for repeat examinations with little risk. It also has the advantage of having the ability to evaluate the entire proliferative marker, MIB-1, respectively (37). Large regions of increased permeability have been associated with decreased survival in glioma patients while a decrease in permeability after treatment was a better predictor of survival than enhancing tumor volume or FLAIR tumor volume (38).
In transforming low-grade gliomas, an increase in rCBV may reflect the "angiogenic switch" whereby an increase in microvascular density occurs well before disruption of the blood-brain barrier. Danchaivijitr et al. demonstrated that in transforming low-grade glioma, DSC MRI perfusion imaging can demonstrate significant increases in rCBV up to 12 months before contrast enhancement is apparent on T1-weighted MR images (39).
For those with high-grade gliomas (WHO grade III and grade IV), an elevated maximum pretreatment rCBV > 2.3 was found to be an independent prognostic biomarker for predicting survival (34).
The importance of VEGF and angiogenesis has also led to studies showing a good correlation between vascular permeability and glioma grade. K trans has been shown to correlate with glioma grade, although less so than with rCBV. It appears that the regions of increased rCBV are spatially heterogeneous and different to areas of increased permeability, likely reflecting, in part, the heterogeneity of the glioma vasculature (35, 36) . Fractional blood volume and K trans derived from DCE MR imaging have been found to correlate with glioma grade and the histologic Recent preliminary work suggests that up-regulated cellular and genetic expression of angiogenic and mitotic signatures within glioblastomas, in part, influence anatomic and physiologic imaging such as rCBV and relative ADC (26).
It should be kept in mind that the use of rCBV should be limited to fibrillary astrocytomas because other gliomas, particularly oligodendrogliomas, may demonstrate elevated rCBV regardless of tumor grade (1). rCBV values were correlated with tissue-specimen. For those with necrosis, the rCBV values ranged from 0.21 to 0.71 and in the tumor group the values ranged from 0.55 to 4.64 (40). 8.3% of the tumor group the rCBV values fell within the radionecrosis group range. It appeared that an rCBV > 0.71 predicted tumor growth, whereas an rCBV < 0.71 predicted radionecrosis, with an accuracy of about 95.9%. While it appears that perfusion MR is may be able to differentiate DRN from recurrent tumor (3, 41, 42), clear threshold rCBV values are not yet clear.
Pseudoprogression
Recent attention has been devoted to a condition similar to radiation necrosis attributed to the use of combined chemoradiotherapy in high-grade gliomas. "Pseudoprogression," as it has been termed, appears to occur earlier and more dramatically than that seen with radiotherapy alone (2). It has been noted to occur in up to 20% of patients who have been treated with temozolomide chemoradiotherapy and may explain about half of all cases of increasing lesions and enhancement in those who have undergone chemoradiation (43) . It also appears to be more frequent in patients with a methylated MGMT gene promoter (44).
Pseudoprogression lesions typically decrease in size or stabilize without additional treatment and often remain clinically asymptomatic (43). The histopathological mechanism underlying pseudoprogression is not yet clear, however, it is likely that chemoradiotherapy results in a greater degree of desired tumor-cell and endothelial-cell killing. This in turn may result in edema and abnormal vessel permeability in the tumor area, mimicking tumor progression (43).
Evaluation of the Post-Therapeutic Brain
Differentiating Therapy Induced Necrosis and Recurrent Tumor
It is well known that differentiation of therapy induced necrosis from recurrent/residural tumor using conventional contrast-enhanced MR is difficult. It is often the case that regions of contrast enhancement seen in the post therapeutic brain often contains both residual or recurrent tumor and therapy-related changes. Despite this, much imaging research has been focused on this goal (1).
Delayed radiation necrosis (DRN) is an occlusive vasculopathy (5). During the early phase of DRN, endothelial proliferation may be seen, which may represent "pseudoprogression" discussed below. Radiation-induced endothelial injury results in fibrinoid necrosis of small vessels, endothelial thickening, hyalinization and vascular thrombosis. Over time, this process typically results in obliteration of the vessel lumen. On the other hand, residual/recurrent tumor displays vascular proliferation and angiogenesis without vascular luminal obliteration. So therefore, while there is often enhancement in radiation necrosis, permeability is only mildly elevated because it represents an occlusive vasculopathy, while in recurrent tumor, there is often a very vascular phase with marked elevation of permeability. rCBV is decreased in radiation necrosis while in residual/ recurrent tumor it appears elevated (5) (Figures 3 and 5) .
A recent small study of previously treated high-grade glioma patients with new enhancing lesions was performed where Figure 4 : Kaplan-Meier survival curves for progression-free survival within the low-grade glioma (LGG) group with (rCBV < 1.75) and (rCBV > 1.75) rCBV groups (solid lines) demonstrating a significant difference in time to progression in LGGs stratified by rCBV alone (P < .0001). When comparing HGGs (broken lines), similarly there was a significant difference in progression in HGGs with high (rCBV > 1.75) versus low rCBV (P < .0001). Among subjects with low rCBV (rCBV < 1.75) there was a significant difference between highand low-grade tumors with respect to progression-free survival (P < .047). However, among subjects with high rCBV (rCBV > 1.75), time to progression was not significantly different (P = .266) for low-and high-grade tumors. (Reproduced by permission from Law M, et al. Radiology. 2008 May; 247(2):490-8) . Cancer Research & Treatment, Volume 10, Number 1, February 2011 The use of conventional contrast-enhanced MR (Macdonald criteria) to distinguish true early progression from pseudoprogression appears to be inadequate (45). Robust advanced imaging findings of pseudoprogression have not yet been published, however, preliminary findings suggest a decrease in rCBV as opposed to increased rCBV values seen in recurrent tumor ( Figure 6 ) (46).
Technology in
Evaluation of Recurrent Glioma and Anti-angiogenic Agents
In patients with recurrent high-grade gliomas, anti-angiogenic agents have been advocated as treatment (47). The first of these agents to be studied in glioblastoma was bevacizumab (Avastin), a humanized monoclonal antibody against VEGF-A. Anti-angiogenic agents appear to prolong progression free survival, however, they may not prolong overall survival in these patients. The exact biological actions of these drugs are not known with some believing that the primary effect of these agents may be to reduce vascular permeability and vasogenic edema without killing tumor cells (48). In fact, some tumors appear to become more invasive while on antiangiogenic treatment.
Often these agents result in a marked decrease in contrast enhancement on MRI, however, some patients appear to clinically progress despite absence of radiographic progression according to the Macdonald criteria, which mainly rely on the appearance of enhancing tumor on MRI (48, 49).
The first phase II study utilizing bevacizumab and irinotecan in those with recurrent high-grade glioma demonstrated an overall radiographic response rate of 63% based on Macdonald criteria (50). The 6 months progression free survival was much higher than prior studies, reaching 30% in the GBM group treated with bevacizumab and irinotecan, whereas historically it was reported to be around 15%, although it is still unclear if this new treatment improves overall survival (51).
VEGF receptor inhibitors such as AZD2171 (cediranib) have also been investigated. A recent study with this agent demonstrated a radiographic response rate of about 50% and a 6 months progression free-survival of 27%. The relative tumor vessel size significantly decreased as early as 1 day after the onset of AZD2171 treatment as well as vascular permeability. 
Pseudoresponse
A dramatic decrease in the amount of contrast enhancement can be seen following administration of anti-angiogenic agents such as bevacizumab or cediranib, sometimes as early as 24 hours following a single dose of anti-VEGF therapy. While this would technically be considered a true response according to the Macdonald Criteria, it is unlikely that there has been a significant, if any, anti-tumor effect (54). These changes are best re-classified as a decrease in vascular permeability or vascular response rather than a true tumor "response" (54). The often robust radiological response observed contrasts sharply with the modest survival benefits, if any, that have been reported with these agents (48).
The term "pseudoresponse" has been applied to the imaging response following treatment with anti-angiogenesis agents such as bevacizumab where a rapid decrease in enhancement with high response rates is noted (8, 50) . The decreased enhancement noted in these patients may at least partially result from rapid improvement of the highly permeable vessels from the tumor and not necessarily from antitumor effects. This concept is further supported by improvement on post contrast MRI as well as with K trans , which examines It was also shown that the tumor vessels became abnormal following drug withdrawal and ''renormalized'' after drug resumption. The enhancement volume and permeability were relatively less prior to stopping the medication, increased substantially during withdrawal, and then again regressed after AZD2171 was resumed, indicating the plasticity of tumor vasculature (8).
In our limited experience, those patients with true response to bevacizumab appear to demonstrate a decrease in enhancing tumor volume as well as decreased rCBV and permeability (5).
Preliminary work utilizing a "vascular normalization index" that incorporates changes in Ktrans, microvessel volume, and circulating collagen IV was found to be closely associated with overall survival and progression free survival in patients given a single dose of cediranib (52).
The use of permeability imaging to evaluate the blood brain barrier to identify when the BBB is maximally open may potentially allow optimal penetration of chemotherapy agents (14). Preliminary results in glioma patients undergoing radiotherapy indicated that the BBB is maximally open after treatment with about 30 Gy of radiation (53). 
Updated Response Criteria for High-Grade Glioma
The Macdonald Criteria is the current basis for evaluating response in patients with high-grade glioma (49). While originally developed for CT scans, they have been adapted to contrast-enhanced MRI and utilize the WHO oncology response criteria of enhancing tumor area, the product of maximal crosssectional enhancing diameters. The criteria also takes into account corticosteroid usage as well as clinical status. There are four categories of response: "complete response," "partial response," "stable disease," and "progression." These criteria remain the most widely used method for evaluating treatment response in clinical trials of high-grade gliomas (59).
According the Macdonald Criteria, an increase of at least 25% in the size of the enhancing lesion would be interpreted as progression and indicate a need for a change in management. However, it must be kept in mind that the presence of enhancement is nonspecific and depicts breakdown of the blood brain barrier that may be secondary to any number of processes such as radiation necrosis, subacute radiation blood brain barrier permeability, even after a single dose of cediranib. This effect was reversible when the drug was stopped. While the actual degree of anti-glioma effect is unclear, it does appear that the decrease in vascular permeability and reduction in vasogenic edema associated with these drugs can result in overall clinical improvement (8).
It appears that patients on bevacizumab may manifest non-enhancing tumor infiltration as increasing regions of non-enhancing T2/FLAIR hyperintensities (8, 55) . Animal models have shown that gliomas may adapt to antiangiogenic agents by facilitated growth of normal vaculature, a process termed "co-option" as well as increased infiltration (56, 57). However, differentiation of non-enhancing infiltrative tumor from peritumoral edema and delayed radiation white matter changes can be difficult.
Reports of non-enhancing tumor progression in patients treated with bevacizumab manifesting with diffusion restriction have been described, however, this needs further validation (5, 58) ( Figure 7 ). in particular, the lack of standardized methods of acquisition, post-processing, and interpretation of perfusion and permeability MR have not been widely adopted, and will be a necessary step to improve their utility in clinical practice.
As related above, the limitations of the Macdonald Criteria, particularly in light of pseudoprogression and pseudoresponse, have become apparent. A detailed discussion of the newly proposed response criteria for high-grade gliomas from the Response Assessment in Neuro-Oncology (RANO) Working Group is beyond the scope of this article and those interested are referred to an excellent review by Wen et al for full discussion (59). However, a few specific points will be highlighted.
With regard to the issue of pseudoprogression, the newly developed response criteria propose that the diagnosis of true progression can only be made within the first 12 weeks after completion of chemoradiotherapy, when pseudoprogression is most common, if most of the new enhancement is present outside of the radiation field or if there is histopathological proof of disease progression.
In the case of pseudoresponse, the newly proposed criteria reiterate the importance of the Macdonald Criteria that a sustained decrease in enhancement of at least 4 weeks is required to be considered a true response.
In the case of progressive disease manifesting as nonenhancing tumor, a situation not accounted for in the Macdonald Criteria, the newly proposed criteria will consider enlarging regions of T2/FLAIR hyperintensity as evidence of tumor progression. However, as outlined above, the differentiation of progressive non-enhancing tumor from other causes of abnormal T2/FLAIR hyperintensity such as peritumoral edema, steroid dosage changes, treatment effects, ischemia, demyelination, infection, and seizures can be difficult. Therefore, the presence of mass effect, presence signal abnormality outside the radiation field, as well as clinical decline may be supportive evidence weighing in favor of disease progression.
Summary
Perfusion and permeability MR are relatively new advanced imaging techniques that have allowed some insight into the pathologic angiogenesis and capillary permeability of gliomas. Conventional contrast-enhanced MRI can be limited in its ability to determine glioma grade as well as to evaluate the post-therapeutic brain. While these methods, as well as other advanced MR techniques such as diffusion imaging, MR spectroscopy, and PET have shown promise to help diagnose and monitor therapy in neuro-oncology, further rigorous clinical studies will be needed to validate their use before they become incorporated into response criteria for high-grade glioma clinical trials. In addition, technical pitfalls,
